Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248665 | 1.00 | SOAT1 (0.39) | SOAT1ALDH1A1TDP1FFAR3TSHR | |
| SCHEMBL13955258 | 0.92 | SOAT1 (0.35) | SOAT1ALDH1A1TDP1FFAR3TSHR | |
| SCHEMBL28196690 | 0.90 | TSHR (0.35) | SOAT1ALDH1A1TSHRHSD17B10CA1 | |
| SCHEMBL28863462 | 0.88 | RNPEP (0.33) | SOAT1TSHRGAA | |
| SCHEMBL962928 | 0.87 | ALDH1A1 (0.43) | SOAT1ALDH1A1TDP1TSHRHSD17B10 | |
| SCHEMBL11792511 | 0.87 | NAAA (0.37) | SOAT1ALDH1A1TDP1FFAR3TSHR | |
| SCHEMBL8332291 | 0.86 | SOAT1 (0.41) | SOAT1ALDH1A1FFAR3HSD17B10LMNA | |
| SCHEMBL1897727 | 0.85 | ALOX15 (0.33) | SOAT1ALDH1A1HSD17B10ALOX15 | |
| SCHEMBL19821804 | 0.85 | SOAT1 (0.39) | SOAT1ALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL1535174 | 0.85 | SOAT1 (0.33) | SOAT1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109730065-B | Attractant composition for frankliniella occidentalis | 黑龙江省植检植保站 | 2022-04-01 | — | — | CN | disclosed |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-03-08 | — | — | US | disclosed |
| EP-3668880-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20200216467-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-07-09 | — | — | US | disclosed |
| EP-3668880-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-06-24 | — | — | EP | disclosed |
| CN-110997682-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2015197860-A2 | NOVEL THAPSIGARGIN ANALOGUES AND METHODS OF PREPARING THEM | UNIVERSITY OF COPENHAGEN (DK) | 2015-12-30 | — | — | WO | disclosed |
| US-20120040930-A1 | TETRACYCLIC TERPENE SERIES COMPOUNDS, METHODS FOR PREPARING SAME, USES THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOUNDS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2004219-A2 | REAGENTS AND METHODS FOR CANCER TREATMENT AND PREVENTION | The Buck Institute for Age Research (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2002058645-A1 | POLYURETHANES, COSMETIC COMPOSITIONS CONTAINING THEM AND METHOD OF PREPARATION | UNILEVER PLC (GB) | 2002-08-01 | — | — | WO | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6011063-A | Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-04 | — | — | US | disclosed |
| US-5994065-A | BLOCKING NON-SPECIFIC SITES ON A SOLID SUPPORT HAVING IMMOBILIZED TARGET LIGANDS COMPRISING NUCLEIC ACIDS BY REACTING WITH AN ACYCLIC OR HETEROCYCLIC CARBOXYLIC ANHYDRIDE; CONTACTING WITH A PROBE | RAPIGENE, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-5308864-A | Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-05-03 | — | — | US | disclosed |
| EP-0480986-A1 | 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991000280-A1 | 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1991-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040930-A1 | TETRACYCLIC TERPENE SERIES COMPOUNDS, METHODS FOR PREPARING SAME, USES THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOUNDS CONTAINING SAME | GGPS1, CYP4A11, CYP46A1 | SOAT1 64/4885ALDH1A1 1851/4885TDP1 2638/4885 |
| US-20200216467-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, IDO1, TDO2 | SOAT1 2170/4885ALDH1A1 554/4885TDP1 419/4885 |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDO2, IDO1, TDO2 | SOAT1 2170/4885ALDH1A1 554/4885TDP1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.